Viking Therapeutics
VKTX
13 hedge funds and large institutions have $1.08M invested in Viking Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,406% more capital invested
Capital invested by funds: $72K → $1.08M (+$1.01M)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
18% more funds holding
Funds holding: 11 → 13 (+2)
Top Buyers
| 1 |
SCM
Sio Capital Management
New York
|
+$731K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$244K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.2K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$26.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$22.4K |
Top Sellers
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$328 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Sio Capital Management
New York
| $699K | +$731K | +554,382 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $259K | +$244K | +185,300 | +914% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $39K | +$41.2K | +31,264 | New |
|
|
ARTA
4
A.R.T. Advisors
New York
| $25K | +$26.8K | +20,300 | New |
|
5
Citadel Advisors
Miami,
Florida
| $21K | +$4.72K | +3,580 | +27% |
|
|
6
Northern Trust
Chicago,
Illinois
| $21K | +$22.4K | +16,962 | New |
|
7
Wells Fargo
San Francisco,
California
| $8K | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $4K | +$1.01K | +767 | +31% |
|
|
AIM
9
Acrospire Investment Management
Chicago,
Illinois
| $3K | +$3.03K | +2,300 | New |
|
10
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $1K | -$328 | -249 | -25% |
|
|
BFA
12
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$84 | +64 | +11% |
|
13
Morgan Stanley
New York
| $1K | +$762 | +578 | +3,400% |
|
|
IA
14
IFP Advisors
Tampa,
Florida
| – | -$6K | -600 | Closed |
|
VKTX Hedge Fund Activity: Q2 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2016, worth a combined $1.08M — up 1,406% from $72K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VKTX positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $731K. The largest seller was IFP Advisors, exiting entirely with an estimated $6K sold.
- 13 institutional investors held Viking Therapeutics (VKTX) as of Q2 2016, up from 11 in Q1 2016.
- Funds reported $1.08M of Viking Therapeutics stock for Q2 2016, up 1,406% quarter-over-quarter.
- 5 funds opened new Viking Therapeutics positions in Q2 2016 and 3 closed out, a net change of +2 holders.
- The largest Viking Therapeutics buyer in Q2 2016 was Sio Capital Management, an estimated $731K added.
- The largest Viking Therapeutics seller in Q2 2016 was IFP Advisors, an estimated $6K sold.
Based on aggregated 13F filings for Q2 2016.